Literature DB >> 8173995

Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility.

J Y Chen1, U P Ling.   

Abstract

BACKGROUND: ABO incompatibility is now the most common cause of isoimmune hemolytic disease of the newborn here. Although hemolytic disease because of ABO incompatibility is clinically milder than that from Rh incompatibility, severe hemolysis occasionally occurs, and some cases require exchange transfusion. It is desirable to assess the accuracy of a group of tests to predict the development of neonatal hyperbilirubinemia in ABO incompatibility. Then, early treatment is available for minimizing the frequency of exchange transfusion.
METHODS: Eighty-eight healthy full-term newborn infants born to blood group 0 mothers were studied and divided into four groups. Each baby weighed 2.5 Kg or more, had no evidence of G-6-PD deficiency. Group 1 consisted of 29 blood group A or B infants with hyperbilirubinemia (serum bilirubin levels > or = 15 mg/dl) and/or icterus praecox. Group 2 consisted of 24 blood group A or B infants without hyperbilirubinemia (serum bilirubin levels < 15 mg/dl). Group 3 consisted of 7 blood group 0 neonates with hyperbilirubinemia. Group 4 consisted of 28 blood group 0 neonates without hyperbilirubinemia. Titers of maternal IgG anti-A and anti-B antibodies were measured. Cord blood was used to performed direct Coombs' test and for bilirubin level determinations.
RESULTS: A total of 18 (62.1%) mothers had IgG anti-A or anti-B titers > or = 512X in Group 1. The majority of mothers (91.5%) in Group 2, 3 and 4 had anti-A or anti-B titers < or = 128X. Thirteen (44.8%) neonates in Group 1 had positive direct Coombs' test of the cord blood. Only one neonate (4.2%) in Group 2 and one neonate (3.6%) in Group 4 had positive direct Coombs' test. A total of 12 neonates (41.4%) in Group 1 had cord bilirubin levels > or = 4 mg/dl, whereas none in the other groups had cord bilirubin levels > or = 4 mg/dl.
CONCLUSIONS: ABO incompatible newborn infants with maternal IgG anti-A or anti-B titers > or = 512X, cord bilirubin levels > or = 4 mg/dl or positive direct Coombs' test of the cord blood represent a "high risk" category, and should be placed in hospital where frequent re-evaluation and appropriate therapy are available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173995

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi (Taipei)        ISSN: 0578-1337


  4 in total

Review 1.  Haemolytic disease of the newborn.

Authors:  Neil A Murray; Irene A G Roberts
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

Review 2.  Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn.

Authors:  Morten Hanefeld Dziegiel; Grethe Risum Krog; Anne Todsen Hansen; Marianne Olsen; Birgitte Lausen; Lone Nikoline Nørgaard; Thomas Bergholt; Klaus Rieneck; Frederik Banch Clausen
Journal:  Transfus Med Hemother       Date:  2021-09-08       Impact factor: 3.747

3.  Evaluation of neonatal jaundice in the Makkah region.

Authors:  Abdulaziz Alkhotani; Essam Eldin Mohamed Nour Eldin; Amal Zaghloul; Shakil Mujahid
Journal:  Sci Rep       Date:  2014-04-25       Impact factor: 4.379

4.  Prediction of ABO hemolytic disease of the newborn using pre- and perinatal quantification of maternal anti-A/anti-B IgG titer.

Authors:  Grethe R Krog; Mette L Donneborg; Bo M Hansen; Henriette Lorenzen; Frederik B Clausen; Kristian V Jensen; Anette Kjærbye-Thygesen; Per Albertsen; Finn Ebbesen; Thomas Bergholt; Mette K Smed; Morten H Dziegiel
Journal:  Pediatr Res       Date:  2020-11-10       Impact factor: 3.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.